Next Article in Journal
Bioinspired versus Enzymatic Oxidation of Some Homologous Thionine Dyes in the Presence of Immobilized Metalloporphyrin Catalysts and Ligninolytic Enzymes
Next Article in Special Issue
Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis
Previous Article in Journal
Antarctic Krill Oil Diet Protects against Lipopolysaccharide-Induced Oxidative Stress, Neuroinflammation and Cognitive Impairment
Previous Article in Special Issue
Human Skin Permeation Studies with PPARγ Agonist to Improve Its Permeability and Efficacy in Inflammatory Processes
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(12), 2561;

Adjuvant Biological Therapies in Chronic Leg Ulcers

Primary Care Research Unit of Bizkaia, BioCruces Health Research Institute, 48014 Bilbao, Spain
Preventive Medicine and Public Health Department, Faculty of Medicine and Odontology, Universidad del País Vasco/Euskal Herriko Unibertsitatea UPV/EHU, University of the Basque Country, 48940 Lejona, Spain
Enkarterrri-Ezkerraldea-Cruces Health Region, Basque Health Service (Osakidetza), 48903 Barakaldo, Spain
Bilbao-Basurto Health Region, Basque Health Service (Osakidetza), 48014 Bilbao, Spain
Regenerative Medicine Laboratory, BioCruces Health Research Institute, Cruces University Hospital, 48903 Barakaldo, Spain
Author to whom correspondence should be addressed.
Received: 3 November 2017 / Revised: 22 November 2017 / Accepted: 28 November 2017 / Published: 28 November 2017
(This article belongs to the Special Issue Inflammatory Skin Conditions 2017)
Full-Text   |   PDF [1746 KB, uploaded 29 November 2017]   |  


Current biological treatments for non-healing wounds aim to address the common deviations in healing mechanisms, mainly inflammation, inadequate angiogenesis and reduced synthesis of extracellular matrix. In this context, regenerative medicine strategies, i.e., platelet rich plasmas and mesenchymal stromal cell products, may form part of adjuvant interventions in an integral patient management. We synthesized the clinical experience on ulcer management using these two categories of biological adjuvants. The results of ten controlled trials that are included in this systematic review favor the use of mesenchymal stromal cell based-adjuvants for impaired wound healing, but the number and quality of studies is moderate-low and are complicated by the diversity of biological products. Regarding platelet-derived products, 18 controlled studies investigated their efficacy in chronic wounds in the lower limb, but the heterogeneity of products and protocols hinders clinically meaningful quantitative synthesis. Most patients were diabetic, emphasizing an unmet medical need in this condition. Overall, there is not sufficient evidence to inform routine care, and further clinical research is necessary to realize the full potential of adjuvant regenerative medicine strategies in the management of chronic leg ulcers. View Full-Text
Keywords: biological therapies; chronic leg ulcer; platelet rich plasma; bone marrow concentrates; stromal vascular fraction; mesenchymal stromal cells biological therapies; chronic leg ulcer; platelet rich plasma; bone marrow concentrates; stromal vascular fraction; mesenchymal stromal cells

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Burgos-Alonso, N.; Lobato, I.; Hernández, I.; Sebastian, K.S.; Rodríguez, B.; Grandes, G.; Andia, I. Adjuvant Biological Therapies in Chronic Leg Ulcers. Int. J. Mol. Sci. 2017, 18, 2561.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top